Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) have earned an average rating of “Moderate Buy” from the fifteen brokerages that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and thirteen have issued a buy rating on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $38.00.

A number of analysts recently weighed in on VRDN shares. Needham & Company LLC lowered their price objective on shares of Viridian Therapeutics from $42.00 to $32.00 and set a “buy” rating for the company in a research note on Monday, March 30th. HC Wainwright lowered their price objective on shares of Viridian Therapeutics from $34.00 to $22.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Viridian Therapeutics in a research note on Wednesday, January 21st. Truist Financial lowered their price objective on shares of Viridian Therapeutics from $41.00 to $40.00 and set a “buy” rating for the company in a research note on Thursday, January 8th. Finally, Wall Street Zen lowered shares of Viridian Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th.

Viridian Therapeutics Stock Up 0.4%

NASDAQ:VRDN opened at $13.96 on Wednesday. Viridian Therapeutics has a 1-year low of $9.90 and a 1-year high of $34.29. The company has a 50-day moving average of $27.58 and a 200 day moving average of $27.82. The firm has a market cap of $1.43 billion, a PE ratio of -4.24 and a beta of 1.16. The company has a debt-to-equity ratio of 0.08, a current ratio of 12.65 and a quick ratio of 12.65.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings data on Thursday, February 26th. The company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.18). Viridian Therapeutics had a negative return on equity of 83.25% and a negative net margin of 483.57%.The business had revenue of $0.13 million during the quarter, compared to analysts’ expectations of $15.75 million. As a group, research analysts anticipate that Viridian Therapeutics will post -4.03 EPS for the current fiscal year.

Viridian Therapeutics News Summary

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: Goldman Sachs cut its price target from $36 to $31 but kept a “buy” rating, implying substantial upside versus the current price and signaling continued analyst conviction. Benzinga
• Positive Sentiment: Royal Bank of Canada lowered its target from $42 to $30 but retained an “outperform” rating, again indicating analysts still see long‑term value despite near‑term headwinds. Benzinga
• Neutral Sentiment: Coverage roundup: a Globe & Mail piece groups Viridian with other healthcare names and summarizes recent analyst commentary — useful context but no new company‑specific catalyst. Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN) and Bristol-Myers Squibb (BMY)
• Negative Sentiment: Competitive clinical risk: Amgen reported positive Phase 3 results for a thyroid eye disease program (TEPEZZA OBI trial reported a 77% proptosis response), which investors view as direct competition to Viridian’s lead program and has been cited as a main reason for recent selling pressure. Why Is Viridian Therapeutics Stock Sinking Monday?
• Negative Sentiment: Press coverage highlights the Amgen link as the driver of the drop, increasing investor concern about VRDN’s addressable market and near‑term commercial prospects. Viridian Therapeutics Stock Is Tanking. Why the Drop Is Linked to This Amgen Study.
• Negative Sentiment: Sentiment/flow signal: unusual options activity — ~7,501 put contracts purchased (a large multiple of typical volume) — indicating hedging or speculative bearish bets that can accelerate downside moves in volatile sessions.
• Negative Sentiment: MSN and other outlets note VRDN has fallen to 9‑month lows amid the Amgen developments, underscoring the short‑term negative narrative investors are reacting to. VRDN stock falls to 9-month lows – what’s the Amgen connection?

Hedge Funds Weigh In On Viridian Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. MetLife Investment Management LLC raised its holdings in Viridian Therapeutics by 0.8% in the fourth quarter. MetLife Investment Management LLC now owns 43,985 shares of the company’s stock worth $1,369,000 after purchasing an additional 356 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Viridian Therapeutics by 0.3% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 139,360 shares of the company’s stock worth $4,337,000 after purchasing an additional 380 shares in the last quarter. US Bancorp DE raised its holdings in Viridian Therapeutics by 23.2% in the third quarter. US Bancorp DE now owns 2,457 shares of the company’s stock worth $53,000 after purchasing an additional 463 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Viridian Therapeutics by 1.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company’s stock worth $669,000 after purchasing an additional 876 shares in the last quarter. Finally, Virtus Investment Advisers LLC raised its holdings in Viridian Therapeutics by 13.4% in the fourth quarter. Virtus Investment Advisers LLC now owns 8,233 shares of the company’s stock worth $256,000 after purchasing an additional 971 shares in the last quarter.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.